21 November, 2006 GAITHERSBURG, Md.–(BUSINESS WIRE)–Nov. 21, 2006–Emergent BioSolutions Inc. (NYSE:EBS), a biopharmaceutical company that develops vaccines and therapeutics for biodefense and commercial applications and manufactures the only anthrax vaccine approved by the U.S. Food and Drug Administration (FDA), today announced it will be celebrating the Company’s recently completed initial public offering with the ringing of the opening bell of the New York Stock Exchange by Fuad El-Hibri, chairman and chief executive officer, on Wednesday November 22, 2006. “Throughout the Company’s history, our people, science and technology have contributed significantly to safeguarding millions of military personnel and the general population through the delivery of a safe and effective countermeasure against the threat of anthrax infection,” said Mr. El-Hibri. “Tomorrow’s ringing of the opening bell is an opportunity to celebrate our Company and our achievements thus far, while acknowledging the commitment and support of our employees, customers and, now, investors who continue to drive our success.” Emergent BioSolutions’ common stock began trading on November 15, 2006 under the symbol EBS. Emergent is a biopharmaceutical company focused on the development, manufacture and commercialization of immunobiotics, such as vaccines and immune globulins, that induce or assist the body’s immune system to prevent or treat disease. The Company operates in two business segments: biodefense and commercial. In its biodefense business, the Company develops and commercializes immunobiotics for use against biological agents that are potential weapons of bioterrorism. In its commercial business, the Company develops immunobiotics for use against infectious diseases with significant unmet or underserved medical needs. The Company’s marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the FDA for the prevention of anthrax infection. For more information about BioThrax, please review the package insert located on the Company’s website www.emergentbiosolutions.com. In addition to BioThrax(R), the Company’s biodefense product portfolio includes three biodefense product candidates in preclinical development and a next generation anthrax vaccine program with product candidates in preclinical and Phase I clinical development. The Company’s commercial product portfolio includes a typhoid vaccine candidate and a hepatitis B therapeutic vaccine candidate, both of which are in Phase II clinical development, one vaccine candidate in Phase I clinical development and two vaccine candidates in preclinical development. Safe Harbor Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management and any other statements containing the words “believes”, “expects”, “anticipates”, “plans”, “estimates” and similar expressions are forward-looking statements. There are a number of important factors that could cause Emergent’s actual results to differ materially from those indicated by such forward-looking statements, including our plans for future sales of BioThrax; our plans to pursue label expansions and improvements for BioThrax; our plans to expand our manufacturing facilities and capabilities; the rate and degree of market acceptance and clinical utility of our products; our ongoing and planned development programs; preclinical studies and clinical trials; our ability to identify and acquire or in license products and product candidates that satisfy our selection criteria; the potential benefits of our existing collaboration agreements and our ability to enter into selective additional collaboration arrangements; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; our commercialization, marketing and manufacturing capabilities and strategy; our intellectual property portfolio; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other factors identified in the Company’s Registration Statement on Form S-1 and subsequent reports filed with the SEC. The Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.www.emergentbiosolutions.com